Merck Serono and the BioRN Cluster
Merck Serono is the division for innovative prescription pharmaceuticals of MerckKGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs.
Headquartered in Geneva, Switzerland, Merck Serono is active on all continents, with around 17,000 employees worldwide. In the United States and Canada, EMD Serono operates through separately incorporated affiliates.
Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases. Biotech products generate around 60% of Merck Serono’s sales.
Excellence in research and developmentis a key success factor for Merck Serono. With an integrated R&D capability organized around 4 main hubs in Darmstadt, Geneva, Boston and Beijing, as well as a network of alliances with other biopharmaceutical companies and academic groups, Merck Serono invests around 22% of total revenues or over € 1bn each year to discover and develop new therapies.
Being an active partner in local scientific networks around our hubs such as the Rhine Neckar biotech cluster is an integral part of our strategy and one of the keys of success. It is very valuable to Merck Serono to be able to participate to and benefit from such a dynamic environment that features a high density of both world-class academic institutions and leading research-based biopharmaceutical companies.
The BioRN cluster is a cradle for innovation and technology, in which the close proximity allows frequent exchanges between partners, and these contacts can be leveraged to result in further collaborations when mutual interests are identified. Merck Serono has now a number of promising collaborative projects in the region, including a prominent one on tumor stem cells with HISTEM and the German Cancer Research Centre.
For further information, please visit www.merckserono.com.
© 2013 BioRN Cluster Management GmbH • All Rights Reserved • Contact & Legal Notice